The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Efficacy of systemic morpholino exon‐skipping in duchenne dystrophy dogs
Open accessAbstract
Objective: Duchenne muscular dystrophy (DMD) is caused by the inability to produce dystrophin protein at the myofiber membrane. A method to rescue dystrophin production by antisense oligonucleotides, termed exon‐skipping, has been reported for the mdx mouse and in four DMD patients by local intramuscular injection. We sought to test efficacy and toxicity of intravenous oligonucleotide (morpholino)‐induced exon skipping in the DMD dog model. Methods: We tested a series of antisense drugs singly and as cocktails, both in primary cell culture, and two in vivo delivery methods (intramuscular injection and systemic intravenous injection). The efficiency and efficacy of multiexon skipping (exons 6–9) were tested at the messenger RNA, protein, histological, and clinical levels. Results: Weekly or biweekly systemic intravenous injections with a three‐morpholino cocktail over the course of 5 to 22 weeks induced therapeutic levels of dystrophin expression throughout the body, with an average of about 26% normal levels. This was accompanied by reduced inflammatory signals examined by magnetic resonance imaging and histology, improved or stabilized timed running tests, and clinical symptoms. Blood tests indicated no evidence of toxicity. Interpretation: This is the first report of widespread rescue of dystrophin expression to therapeutic levels in the dog model of DMD. This study also provides a proof of concept for systemic multiexon‐skipping therapy. Use of cocktails of morpholino, as shown here, allows broader application of this approach to a greater proportion of DMD patients (90%) and also offers the prospect of selecting deletions that optimize the functionality of the dystrophin protein. Ann Neurol 2009
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abràmoff, M. D., Magalhães, P. J., & Ram, S. J. (2004) · Utrecht University Repository (Utrecht University) · Cited by 15,108
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Self-citationMorpholino Antisense Oligomers: Design, Preparation, and Properties
SUMMERTON, J., & WELLER, D. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.187 · Cited by 1,116
Koenig, M., Beggs, A. H., Moyer, M., Scherpf, S., Heindrich, K., Bettecken, T., Meng, G., Müller, C. R., Lindlöf, M., Kääriäinen, H. A., et al. (1989) · Europe PMC (PubMed Central) · Cited by 961
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051
van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073108 · Cited by 781
Very mild muscular dystrophy associated with the deletion of 46% of dystrophin
England, S. B., Nicholson, L. V. B., Johnson, M. A., Forrest, S. M., Love, D. R., Zubrzycka-Gaarn, E. E., Bulman, D. E., Harris, J. B., & Davies, K. E. (1990) · Nature · doi:10.1038/343180a0 · Cited by 623 · cited 1×
“Some BMD patients with deletions as large as 33 exons (46% of the gene) can show little or no clinical symptoms, with only increased serum creatine kinase concentration.(4) This raises the possibility of using antisense-mediated removal of exons carrying nonsense mutations, or whose presence disrupts the open reading…”
BackgroundAlter, J., Lou, F., Rabinowitz, A., Yin, H., Rosenfeld, J., Wilton, S. D., Partridge, T. A., & Lu, Q. L. (2006) · Nature Medicine · doi:10.1038/nm1345 · Cited by 494
Self-citationSharp, N. J. H., Kornegay, J. N., Van Camp, S. D., Herbstreith, M. H., Secore, S. L., Kettle, S., Hung, W.-Y., Constantinou, C. D., Dykstra, M. J., Roses, A. D., et al. (1992) · Genomics · doi:10.1016/0888-7543(92)90210-j · Cited by 362
Dystrophin–glycoprotein complex: Its role in the molecular pathogenesis of muscular dystrophies
Matsumura, K., & Campbell, K. P. (1994) · Muscle & Nerve · doi:10.1002/mus.880170103 · Cited by 311
Dunckley, M. G., Manoharan, M., Villiet, P., Eperon, I. C., & Dickson, G. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.7.1083 · Cited by 255
Jearawiriyapaisarn, N., Moulton, H. M., Buckley, B., Roberts, J., Sazani, P., Fucharoen, S., Iversen, P. L., & Kole, R. (2008) · Molecular Therapy · doi:10.1038/mt.2008.120 · Cited by 244
Béroud, C., Tuffery-Giraud, S., Matsuo, M., Hamroun, D., Humbertclaude, V., Monnier, N., Moizard, M.-P., Voelckel, M.-A., Calemard, L. M., Boisseau, P., et al. (2007) · Human Mutation · doi:10.1002/humu.20428 · Cited by 207
McClorey, G., Moulton, H. M., Iversen, P. L., Fletcher, S., & Wilton, S. D. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302800 · Cited by 207
Antisense-Induced Multiexon Skipping for Duchenne Muscular Dystrophy Makes More Sense
Aartsma-Rus, A., Janson, A. A. M., Kaman, W. E., Bremmer-Bout, M., van Ommen, G.-J. B., den Dunnen, J. T., & van Deutekom, J. C. T. (2004) · The American Journal of Human Genetics · doi:10.1086/381039 · Cited by 200
Araishi, K., Sasaoka, T., Imamura, M., Noguchi, S., Hama, H., Wakabayashi, E., Yoshida, M., Hori, T., & Ozawa, E. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.9.1589 · Cited by 161
Jankowski, R. J., Haluszczak, C., Trucco, M., & Huard, J. (2001) · Human Gene Therapy · doi:10.1089/104303401300057306 · Cited by 135
Canine X-Linked Muscular Dystrophy in Japan (CXMDJ).
Shimatsu, Y., KATAGIRI, K., FURUTA, T., Nakura, M., Tanioka, Y., Yuasa, K., Tomohiro, M., Kornegay, J. N., Nonaka, I., & Takeda, S. (2003) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.52.93 · Cited by 125
Self-citationYoshimura, M., Sakamoto, M., Ikemoto‐Uezumi, M., Mochizuki, Y., Yuasa, K., Miyagoe‐Suzuki, Y., & Takeda, S. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.025 · Cited by 118
Self-citationAartsma-Rus, A. M., de Winter, C. L., Janson, A. A. M., Kaman, W. E., van Ommen, G. B., den Dunnen, J. T., & van Deutekom, J. C. T. (2005) · Oligonucleotides · doi:10.1089/oli.2005.15.284 · Cited by 111
Yokota, T., Lu, Q., Morgan, J. E., Davies, K. E., Fisher, R., Takeda, S., & Partridge, T. A. (2006) · Journal of Cell Science · doi:10.1242/jcs.03000 · Cited by 93
Self-citationNakamura, A., Yoshida, K., Fukushima, K., Ueda, H., Urasawa, N., Koyama, J., Yazaki, Y., Yazaki, M., Sakai, T., Haruta, S., et al. (2008) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2006.12.012 · Cited by 92
Self-citationAartsma-Rus, A. M., Kaman, W. E., Weij, R., den Dunnen, J. T., van Ommen, G. B., & van Deutekom, J. C. T. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.02.022 · Cited by 91
Shimatsu, Y., Yoshimura, M., Yuasa, K., Urasawa, N., Tomohiro, M., Nakura, M., Tanigawa, M., Nakamura, A., & Takeda, S. (2005) · PubMed · Cited by 79
Self-citationAntisense-induced exon skipping for duplications in Duchenne muscular dystrophy
Aartsma-Rus, A. M., Janson, A. A. M., van Ommen, G. B., & van Deutekom, J. C. T. (2007) · BMC Medical Genetics · doi:10.1186/1471-2350-8-43 · Cited by 77
Optimizing exon skipping therapies for DMD.
Yokota, T., Duddy, W. J., & Partridge, T. A. (2007) · Europe PMC (PubMed Central) · Cited by 67
Self-citationYugeta, N., Urasawa, N., Fujii, Y., Yoshimura, M., Yuasa, K., Wada, M. R., Nakura, M., Shimatsu, Y., Tomohiro, M., Takahashi, A., et al. (2006) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-6-47 · Cited by 67
Self-citationLiang, K. W., Nishikawa, M., Liu, F., Sun, B., Ye, Q., & Huang, L. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302239 · Cited by 67
Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy
Yokota, T., Pistilli, E. E., Duddy, W. J., & Nagaraju, K. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.6.831 · Cited by 53
Self-citationInduction of revertant fibres in the mdx mouse using antisense oligonucleotides
Fall, A., Johnsen, R. D., Honeyman, K., Iversen, P. L., Fletcher, S., & Wilton, S. D. (2006) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-4-3 · Cited by 38
Cited by
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M. E., Bourke, J., Wells, D. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60756-3 · Cited by 878
Eteplirsen for the treatment of Duchenne muscular dystrophy
Mendell, J. R., Rodino‐Klapac, L. R., Sahenk, Z., Roush, K., Bird, L., Lowes, L. P., Alfano, L., Gomez, A. M., Lewis, S., Kota, J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23982 · Cited by 817
Kinali, M., Arechavala-Gomeza, V., Feng, L., Cirak, S., Hunt, D., Adkin, C., Guglieri, M., Ashton, E., Abbs, S., Nihoyannopoulos, P., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70211-x · Cited by 653
Splice-switching antisense oligonucleotides as therapeutic drugs
Havens, M. A., & Hastings, M. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw533 · Cited by 538
Metadata
- Authors
- Yokota, T., Lu, Q., Partridge, T., Kobayashi, M., Nakamura, A., Takeda, S., & Hoffman, E.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2009-03-13
- Volume
- 65
- Issue
- 6
- Pages
- 667-676
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2062442451
- Cited by
- 398
- References
- 29
- FWCI
- 16.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.